PGN36
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) [1][2].
Product Specifications
CAS Number
1564253-75-3
UNSPSC
12352005
Target
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pgn36.html
Purity
99.74
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=[N+](C1=CC2=C(N(CC3=CC=CC=C3)N=C2OCC4CCCCC4)C=C1)[O-]
Molecular Formula
C21H23N3O3
Molecular Weight
365.43
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CB2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ADAM21 (Disintegrin and Metalloproteinase Domain-containing Protein 21, ADAM 21, MGC125389)
